AI Summary & Key Takeaways
AI InsightCONCLUSION: Efficacy of docetaxel and paclitaxel are the same in terms of hystopathological findings of second look laparatomy in the treatmet of first-line epithelial ovarian cancer.
📌 3 Key Takeaways
Abstract
OBJECTIVE: To evaluate and compare efficacy of docetaxel and paclitaxel combining with carboplatin in the first line chemotherapy of epithelial ovarian carcinoma according to hystopathological findings of second look laparatomy. STUDY DESIGN: Thirty two patients having stage II-IV epithelial ovarian cancer (17 cases in the paclitaxel-carboplatin group,15 cases in the docetaxel-carboplatin group) and operated in Department of Obstetrics and Gynecology, Division of Gynecologic Oncology were entered in this study. The cases were randomized for the treatment. All cases had inform-consent about the treatment options and second look procedures. The cases who completed chemotherapy and had a second look laparatomy were included the study. Pathological responses were evaluated with second look findings proved with biopsy. Statistical analyses were performed with Chi square and Mann-Whitney U tests. Survival analyses were calculated with using Kaplan-Meier survival analyses and Log Rank test. P>0.05 was accepted for statistical significance. RESULTS: There were no differences in demographic characteristics and rate of optimal cytoreduction between two groups. Eight cases (47,1%) in the paclitaxel-carboplatin group and 3 cases (20%) in the docetaxel-carboplatin group were hystopathological tumor positive in the second look operation without statistically significance. Also there was no significant difference between two groups in mean survival time(p 0.06). CONCLUSION: Efficacy of docetaxel and paclitaxel are the same in terms of hystopathological findings of second look laparatomy in the treatmet of first-line epithelial ovarian cancer.
Özet
Epitelyal over karsinomlannin ilk basamak kemoterapisinde karboplatin ile birlikte paklitaksel ve dosetakselin etkinliğinin ikincil bakış laparatomisinin histopatolojik bulgularına göre değerlendirilmesi ve karşılaştırılması. Evre II-IV epitelyal over kanserli (17 vaka paklitaksel-karbopla-tin, 15 vaka dosetaksel-karboplatin grubunda) ve Kadın Hastalıkları ve Doğum Departmanı Jinekolojik Onkoloji Ünitesinde öpere edilen 32 hasta çalışmaya alındı. Vakalar tedaviler için randomize edildi. Tüm vakalardan tedaviler ve ikincil bakış laparatomisi için bilgilendirilmiş onam alındı. Kemoterapisini tamamlayan ve ikincil bakış laparatomisi yapılan hastalar çalışmaya dahil edildi. Patolojik cevap biyopsi ile kanıtlanmış ikincil bakış laparatomi bulguları ile değerlendirildi. İstatistiksel analizler X2 ve Mann-Whitney U testleri ile yapıldı. Survival analizleri Kaplan-Meier yaşam analizi ve log Rank testi kullanılarak yapıldı. P 0,05). Sekiz kişi pakli-taksel, 3 kişi dosetaksel grubunda ikincil bakış laparatominin histopatoloji bulgularına göre istatistiksel anlamlı olmayarak tümör saptandı. Keza ortalama yaşam süresi iki grup arasında farksızdı (p 0,06). İkincil bakış laparatomisinin histopatolojik bulgularına göre dosetaksel ve paklitaksel epitelyal over kanserlerinin birincil tedavisinde benzer etkilidir.